AstraZeneca India gets DCGI approval to market drug treating breast cancer

Drug firm AstraZeneca India on Friday said it has received an approval from the Drugs Controller General of India to market its drug for the treatment of breast cancer

AstraZeneca
Image: Reuters
Press Trust of India New Delhi
2 min read Last Updated : Aug 20 2022 | 1:37 AM IST

Drug firm AstraZeneca India on Friday said it has received an approval from the Drugs Controller General of India to market its drug for the treatment of breast cancer.

The Drugs Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with early breast cancer, who have previously been treated with neoadjuvant or adjuvant chemotherapy.

The approval was based on results from the OlympiA Phase III trial, which suggested that Olaparib demonstrated a statistically significant and clinically meaningful improvement, with an overall survival benefit, AstraZeneca India said in a statement.

With the DCGI's nod, Lynparza is now approved in the US, EU, Japan, India and several other countries for the treatment of early-stage breast cancer, it added.

Currently, Lynparza is the first and only approved medicine targeting BRCA (Breast Cancer gene) mutations in early-stage breast cancer.

"The regulatory approval of Lynparza...reinforces our growing capabilities in innovation and clinical research for providing holistic solutions for cancer treatment in India," AstraZeneca India Managing Director and Country President Gagandeep Singh noted.

Breast cancer is one of the most diagnosed cancer worldwide with an estimated 23 lakh patients diagnosed per year.

Non-Communicable Diseases (NCDs) like cancer in India today account for 62 per cent of all deaths and 48 per cent of preventable premature deaths.

"Our oncology portfolio has been consistently growing in the range of 40 to 50 per cent over the last 3 years...At AstraZeneca, we see huge potential in the utilisation of cancer-related drugs for wider scope," Singh stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :AstraZenecaIndia

First Published: Aug 19 2022 | 7:04 PM IST

Next Story